Home › NDC Lookup › RxCUI directory › RxCUI 2371766

Elagolix 300 MG Oral Capsule — RxCUI 2371766

RxNorm drug concept · Semantic clinical drug
RxCUI 2371766 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2371766
Official nameElagolix 300 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)500 prescriptions · 7 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Elagolix: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It manages moderate to severe pain from endometriosis. Your prescriber picks the regimen based on your symptoms and health, and how long you can take it is limited.
  • Take your tablet at about the same time each day, with or without food. If you miss one, take it the same day when you remember, then go back to your normal schedule. Don't take ex...
  • Hot flushes and night sweats, headache, nausea, and trouble sleeping are common. Some people also have anxiety, joint pain, mood changes, or no periods. Nausea and hot flushes ofte...
  • Elagolix can cause bone loss, and it increases with higher doses and longer use. The loss may not fully reverse after stopping. That's why your prescriber uses the lowest effective...
📖 Read our full Elagolix guide →

🕸️ Concept Web — How Elagolix 300 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Elagolix 300 MG Oral Capsule RxCUI 2371766

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Elagolix 2049846
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Elagolix Oral Capsule 2371765
    • Elagolix Oral Product 2049849
    • Elagolix Pill 2049850
    • Oral Capsule 316965
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Elagolix 300 MG 2371759
  4. Packs 2

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 10 of 10 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2371766 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00074-1017-14 1 BLISTER PACK in 1 CARTON (0074-1017-14) / 1 KIT in 1 BLIS... Oriahnn AbbVie Inc. 2020-09-24
00074-1017-56 4 BLISTER PACK in 1 CARTON (0074-1017-56) / 1 KIT in 1 BLIS... Oriahnn AbbVie Inc. 2020-05-29
Observed labelers: AbbVie Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.